Douglas Drysdale

Patent Director

Douglas acts for a broad range of clients within the life sciences and chemical fields. His clients benefit from his candid, pragmatic and commercially-focused advice. He has a particularly strong reputation with the university sector, having acted for several top-tier universities in protecting and enforcing IP, and also in negotiating commercial agreements and resolving contentious matters. Other notable clients include major global medical device and chemical companies, and many growing SMEs. He is also highly experienced in oppositions and appeals before the European Patent Office. 

Having obtained a first class honours in Molecular Biology from the University of Aberdeen, Douglas decided to pursue a career as a patent attorney. He then completed the MSc in the Management of Intellectual Property Law at Queen Mary College, University of London, giving him a firm grounding in IP law.

Douglas joined HGF in 2011 from a leading Scottish-based international IP firm where he began his career, having risen rapidly there to the role of Director. During this time he qualified as UK and European Patent Attorney in record time and built up a strong reputation within the profession.

 Particular areas of focus for Douglas’s practice include genetic engineering (including gene editing), synthetic biology, industrial biotechnology, biological therapies and antibodies, gene therapy, diagnostics (including biomarkers and imaging technologies), personalised medicine, regenerative therapy and medicinal devices. 

Douglas serves on the Examination Committee for the European Qualification Examination, which assesses candidates for qualification as European Patent Attorneys. With a role in setting and marking the ‘Opposition’ paper, Douglas uses this opportunity to both contribute to the profession, and to ensure he stays up to date at the cutting edge of European patent law.